Enlivex Therapeutics Ltd. (NASDAQ:ENLV) has earned an average broker rating score of 1.00 (Strong Buy) from the one analysts that provide coverage for the company, Zacks Investment Research reports. One research analyst has rated the stock with a strong buy recommendation.
Brokerages have set a one year consensus price objective of $20.00 for the company and are anticipating that the company will post ($0.25) earnings per share for the current quarter, according to Zacks. Zacks has also given Enlivex Therapeutics an industry rank of 119 out of 255 based on the ratings given to related companies.
Separately, HC Wainwright initiated coverage on shares of Enlivex Therapeutics in a research report on Thursday, January 9th. They set a “buy” rating and a $20.00 price objective on the stock.
Enlivex Therapeutics (NASDAQ:ENLV) last posted its earnings results on Thursday, November 14th. The company reported ($0.23) EPS for the quarter. As a group, equities analysts expect that Enlivex Therapeutics will post -1.06 earnings per share for the current year.
About Enlivex Therapeutics
Enlivex Therapeutics Ltd., a clinical stage immunotherapy company, engages in developing allogeneic drugs for immune system rebalancing. Its product candidate is Allocetra, an immunotherapy candidate for the prevention of complications post bone marrow transplantations; treatment of patients that do not respond to steroid treatment upon occurrence of graft vs host disease post bone marrow transplantations; and prevention of cytokine storms, organ damage, and multiple organ failure in sepsis patients.
Read More: Gap Down Stocks
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Enlivex Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enlivex Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.